C-reactive protein: A physiological activator of interleukin 6 receptor shedding

Journal of Experimental Medicine

Volumn 189, Issue 3, 1999, Pages 599-604

  Jones, Simon A ^a,e   Novick, Daniela ^c   Horiuchi, Sankichi ^d   Yamamoto, Naoki ^d   Szalai, Alexander J ^b   Fuller, Gerald M ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^d TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^e CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Acute phase proteins; Cytokines; Inflammation; Interleukin 6; Soluble receptors

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; ISOPROTEIN; MESSENGER RNA; METALLOPROTEINASE INHIBITOR; PEPTIDE FRAGMENT;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; HUMAN; HUMAN CELL; LEUKOCYTE ACTIVATION; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN INDUCTION; RECEPTOR BINDING; RECEPTOR UPREGULATION; REGULATORY MECHANISM; RNA SPLICING;

ACUTE-PHASE REACTION; C-REACTIVE PROTEIN; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROXAMIC ACIDS; INFLAMMATION MEDIATORS; NEUTROPHILS; PEPTIDE FRAGMENTS; PROTEASE INHIBITORS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, INTERLEUKIN-6; RNA SPLICING; SOLUBILITY;

EID: 0033080801     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.189.3.599     Document Type: Article

References (44)

1. Heinrich, P.C., I. Behrmann, G. Muller-Newen, F. Schaper, and L. Graeve. 1998. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem. J. 334: 297-314.
2. Rose-John, S., and P.C. Heinrich. 1994. Soluble receptors for cytokines and growth factors: their generation and biological function. Biochem. J. 300:281-290.
3. Hirota, H., K. Yoshida, T. Kishimoto, and T. Taga. 1995. Continuous activation of gp130, a signal-transducing receptor component for interleukin-6-related cytokines, causes myocardial hypertrophy in mice. Proc. Natl. Acad. Sci. USA. 92:4862-4866.
4. Mihara, M., Y. Monya, T. Kishimoto, and Y. Ohsugi. 1995. Interleukin-6 (IL-6) induces the proliferation of synovial fibroblastic cells in the presence of soluble IL-6 receptor. Br. J. Rheumatol. 34:321-325.
5. Murakami-Mori, K.T., T. Taga, T. Kishimoto, and S. Nakamura. 1996. The soluble form of the IL-6 receptor (sIL-6Rα) is a potent growth factor for AIDS-associated Kaposi's sarcoma (KS) cells; the soluble form of gp130 is antagonistic for sIL-6R-induced AIDS-KS cell growth. Int. Immunol. 8:595-600.
6. Udagawa, N., N. Takahashi, T. Katagiri, T. Tamura, S. Wada, D.M. Findlay, T.J. Martin, H. Hirota, T. Taga, T. Kishimoto, and T. Suda. 1995. Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells, but not on osteoclast progenitors. J. Exp. Med. 182:1461-1468.
7. Romano, M., M. Sironi, C. Toniati, N. Polentarutti, P. Fruscella, P. Ghezzi, R. Faggioni, W. Luini, V. van Hinsbergh, S. Sozzani, et al. 1997. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity, 6:315-325.
8. Modur, V., Y. Li, G.A. Zimmerman, S.M. Prescott, and T.M. McIncyre. 1997. Retrograde inflammatory signaling from neutrophils to endothelial cells by soluble interleukin-6 receptor alpha. J. Clin. Invest. 100:2752-2756.
9. Tilg, H., E. Trehu, M.B. Atkins, C.A. Dinarello, and J.W. Mier. 1994. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55, Blood, 83:113-118.
10. Xing, Z., J. Gauldie, G. Cox, H. Baumann, M. Jordana, X.-F. Lei, and M.K. Achong. 1998. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J. Clin. Invest. 101:311-320.
11. Müllberg, J., H. Schooltink, T. Stoyan, M. Gunther, L. Graeve, G. Buse, A. Mackiewicz, P.C. Heinrich, and S. Rose-John. 1993. The soluble interleukin-6 receptor is generated by shedding. Eur. J. Immunol. 23:473-480.
12. Müllberg, J., F.H. Durie, C. Otten-Evans, M.R. Alderson, S. Rose-John, D. Cosman, R.A. Black, and K.M. Mohler. 1995. A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor. J. Immunol. 155:5198-5205.
13. Lust, J.A.K., K.A. Donovan, M.P. Kline, P.R. Griepp, R.A. Kyle, and N.J. Maihle. 1992. Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor. Cytokine. 4:96-100.
14. Horiuchi, S., Y. Koyanagi, Y. Zhou, H. Miyamoto, Y. Tanaka, M. Waki, A. Matsumoto, M. Yamamoto, and N. Yamamoto. 1994. Soluble interleukin-6 receptors released from T cells or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism. Eur. J. Immunol. 24:1945-1948.
15. Kotake, S., K. Sato, K.J. Kim, N. Takahashi, N. Udagawa, I. Nakamura, A. Yamaguchi, T. Kishimoto, T. Suda, and S. Kashiwazaki. 1996. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from arthritis patients are responsible for osteoclast-like cell formation. J. Bone Miner. Res. 11:88-95.
16. Kyrtsonis, M.C., G. Dedoussis, C. Zervas, V. Perifanis, C. Baxevanis, M. Stamatelou, and A. Maniatis. 1996. Soluble interleukin-6 receptor (sIL-6R), a new prognostic factor in multiple myeloma. Br. J. Haematol. 93:398-400.
17. Honda, M., S. Yamamoto, M. Cheng, K. Yasukawa, H. Suzuki, T. Saito, Y. Osugi, T. Tokunaga, and T. Kishimoto. 1992. Human soluble IL-6 receptor: its detection and enhanced release by HIV infection J. Immunol. 148:2175-2180.
18. Walev, I., P. Vollmer, M. Palmer, S. Bhakdi, and S. RoseJohn. 1996. Pore-forming toxins trigger shedding of receptors for interleukin-6 and lipopolysaccharide, Proc. Natl. Acad. Sci. USA. 93:7882-7887.
19. Cichy, J., S. Rose-John, J. Potempa, J. Pryjma, and J. Travis. 1997. Oncostatin-M stimulates the expression and release of the IL-6 receptor in human hepatoma HepG2 cells. J. Immunol. 159:5648-5653.
20. 2+ mobilization, while basal release is predominantly the product of differential mRNA splicing in THP-1 cells. Eur. J. Immunol. 28:3514-3522.
21. Novick, D., H. Engelmann, M. Revel, O. Leitner, and M. Rubenstein. 1991. Monoclonal antibodies to the soluble human IL-6 receptor: affinity purification, ELISA, and inhibition of ligand binding. Hybridoma. 10:137-146.
22. Shephard, E.G., S.M. Beer, R. Anderson, A.F. Strachan, A.E. Nel, and F.C. de Beer. 1989. Generation of biologically active C-reactive protein peptides by a neutral protease on the membrane of phorbol myristate acetate-stimulated neutrophils. J. Immunol. 143:2974-2981.
23. Shephard, E.G., R. Anderson, O. Rosen, M.S. Myer, M. Friedkin, A.F. Strachan, and F.C. de Beer. 1990. Peptides generated from C-reactive protein by a neutrophil membrane bound protease J. Immunol. 145:1469-1476.
24. Heuertz, R.M., N. Ahmed, and R.O. Webster. 1996. Peptides derived from C-reactive protein inhibit neutrophil alveolitis. J. Immunol. 156:3412-3417.
25. Arribas, J., L. Coodly, P. Vollmer, T.K. Kishimoto, S. Rose-John, and J. Massagué. 1996. Diverse cell surface protein ectodomains are shed by a system sensitive to metalloprotease inhibitors. J. Biol. Chem. 271:11376-11382.
26. Mohler, K.M., P.R. Sleath, J.N. Fitzner, D.P. Cerretti, M. Alderson, S.S. Kerwar, D.S. Torrance, C. Otten-Evans, T. Greenstreet, K. Weerawarna, et al. 1994. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature. 370:218-220.
27. Bennett, T.A., E.B. Lynam, L.A. Sklar, and S. Rogelj. 1996. Hydroxamic-based metalloprotease inhibitor blocks shedding of L-selectin adhesion molecule from leukocytes. Functional consequences for neutrophil aggregation. J. Immunol. 156: 3093-3097.
28. Pepys, M.B., and M.L. Baltz. 1983. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv. Immunol. 34:141-212.
29. Ganapathi, M.K., L.T. May, D. Schultz, A. Brabenec, J. Weinstein, P.B. Sehgal, and I. Kushner. 1988. Role of interleukin-6 in regulating synthesis of C-reactive protein and serum amyloid A in human hepatoma cell lines. Biochem. Biophys. Res. Commun. 157:271-277.
30. Szalai, A.J., F.W. van Ginkel, S.A. Dalrymple, R. Murray, J.R. McGhee, and J.E. Volanakis. 1998. Testosterone and IL-6 requirements for human C-reactive protein gene expression in transgenic mice. J. Immunol. 160:5294-5299.
31. Yokoyama, A., N. Kohno, Y. Hirasawa, K. Kondo, M. Abe, Y. Inoue, S. Fujioka, S. Fujino, S. Ishida, and K. Hiwada. 1995. Elevation of soluble IL-6 receptor concentration in serum and epithelial lining fluid from patients with interstitial lung diseases. Clin. Exp. Immunol. 100:325-329.
32. Kyriakou, D., H. Papadaki, A.G. Eliopoulos, A. Foudoulakis, M. Alexandrakis, and G.D. Eliopoulos. 1997. Serum soluble IL-6 receptor concentrations correlate with stages of multiple myeloma defined by serum beta 2-microglobulin and C-reactive protein. Int. J. Hematol. 66:367-371.
33. Mitsuyama, K., A. Toyonaga, E. Sasaki, O. Ishida, H. Ikeda, O. Tsuruta, K. Harada, H. Tateishi, T. Nishiyama, and K. Tanikawa. 1995. Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating IL-6. Gut. 36:45-49.
34. Szalai, A.J., A. Agrawal, T.J. Greenhough, and J.E. Volanakis. 1997. C-reactive protein: structural biology, gene expression and host defense function. Immunol. Res. 16:127-136.
35. Kew, R.R., T.M. Hyer, and R.O. Webster. 1990. Human C-reactive protein inhibits neutrophil chemotaxis in vitro: possible implications for adult respiratory distress syndrome. J. Lab. Clin. Med. 115:339-345.
36. Filep, J., and E. Foldes-Filep. 1989. Effects of C-reactive protein on human neutrophil granulocytes challenged with N-formyl-methionyl-leucyl-phenylalanine and platelet-activating factor. Life Sci. 44:517-524.
37. Zouki, C., M. Beauchamp, C. Baron, and J. Filep. 1997. Prevention of in vitro neutrophil adhesion to endothelial cells through shedding of L-selectin by C-reactive protein and peptides derived from C-reactive protein. J. Clin. Invest. 100:522-529.
38. Heuertz, R.M., C.A. Piquette, and R.O. Webster. 1993. Rabbits with elevated serum C-reactive protein exhibit diminished neutrophil infiltration and vascular permeability in C5a-induced alveolitis. Am. J. Pathol. 142:319-328.
39. Ahmed, N., R. Thorley, D. Xia, D. Samols, and R.O. Webster. 1996. Transgenic mice expressing rabbit C-reactive protein exhibit diminished chemotactic factor-induced alveolitis. Am. J. Respir. Crit. Care Med. 153:1141-1147.
40. Desgeorges, A., C. Gabay, P. Silacci, D. Novick, P. Roux-Lombard, G. Grau, J.M. Dayer, T. Vischer, and P.A. Guerne. 1997. Concentrations and origins of soluble interleukin-6 receptor-α in serum and synovial fluid. J. Rheumatol. 24:1510-1516.
41. Barna, B.P., M.J. Thomassen, P. Zhou, J. Pettay, S. Singh-Burgess, and S.D. Deodhar. 1996. Activation of alveolar macrophage TNF and MCP-1 expression in vivo by a synthetic peptide of C-reactive protein. J. Leukocyte Biol. 59: 397-402.
42. Marnell, L.L., C. Mold, M.A. Volzer, R.W. Burlingame, and T.W. Du Clos. 1995. C-reactive protein binds to Fcγ-R1 in transfected COS cells. J. Immunol. 155:2185-2193.
43. Biffl, W.L., E.E. Moorte, F.A. Moore, C.C. Barnett, C.C. Silliman, and V.M. Peterson. 1996. Interleukin-6 stimulates neutrophil production of platelet-activating factor. J. Leukocyte Biol. 59:569-574.
44. Mullen, P.G., A.C. Windsor, C.J. Walsh, A.A. Fowler III, and H.J. Sugerman. 1995. Tumor necrosis factor-alpha and interleukin-6 selectively regulate neutrophil function in vitro. J. Surg. Res. 58:124-130.